We apologise for slow response on live chat as we are experiencing a sudden surge of more than 2000 queries per day! Please email to pr@thailandmedical.news for non-urgent queries. Thank You.
Featuring latest Drug Developments and Treatment Protocols and also Updates about the Pharmaceutical Industry , both in Thailand and abroad, latest USFDA and Thai FDA approvals and also Corporate News with regards to various Pharma companies.
US FDA has approved the Dalteparin Sodium, (Fragmin) which is a low molecular weight heparin(LMWH) for the treatment of of symptomatic venous thromboembolism (VTE) in pediatric patients 1 month of age and older.
Venous thromboembolism (VTE) is a condition in which a blood clot forms most often in the deep veins of the leg, groin or arm (known as deep vein thrombosis, DVT) ...
The U.S. Food and Drug Administration approved Benlysta (belimumab) intravenous (IV) infusion for treatment of children with systemic lupus erythematosus (SLE) - often referred to as simply "lupus" - a serious chronic disease that causes inflammation and damage to various body tissues and organs. This is the first time that the FDA has approved a treatment for pediatric patients with SLE...
French pharmaceutical giant Sanofi on Friday said the European Medicines Agency had conditionally approved its anti-cancer drug Libtayo, the first drug of its kind to be authorised for use in the EU. The drug, also known as CEMIPLIMAB-RWLC is used for for treatment of Advanced Cutaneous Squamous Cell Carcinoma
The tumour-reducing drug is aimed at patients with the second most common form of ski...
Source: American College of Physicians Apr 24, 2019
In the Diabetes Prevention Program (DPP) clinical trial and its long-term follow-up study, among the persons who lost at least 5 percent of their body weight during the first year, long-term maintenance of weight loss was more likely if they had been assigned to treatment with metformin than with placebo or lifestyle intervention. Being older and losing a greater amount of weight in the first year...
A new landmark clinical trial shows that a drug lowers the risk of kidney failure by a third in people with Type 2 diabetes and kidney disease.
"For the first time in 18 years, we have a therapy for patients with Type 2 diabetes and chronic kidney disease that decreases kidney failure," said Kenneth Mahaffey, MD, professor of medicine at the Stanford University School of Medicine and co...
